MHRA paediatric investigation plan

Pneumococcal Polysaccharide Serotype 3 - Diphtheria CRM197 Conjugate (Pneumococcal Polysaccharide Serotype 3 - Diphtheria CRM197 Conjugate)

MHRA paediatric investigation plan MHRA-100920-PIP01-23 · Agreement

Key facts

PIP number MHRA-100920-PIP01-23
Active substances Pneumococcal Polysaccharide Serotype 3 - Diphtheria CRM197 Conjugate, Pneumococcal Polysaccharide Serotype 6A - Diphtheria CRM197 Conjugate, Pneumococcal Polysaccharide Serotype 7F - Diphtheria CRM197 Conjugate, Pneumococcal Polysaccharide Serotype 19A - Diphtheria CRM197 Conjugate, Pneumococcal Polysaccharide Serotype 22F - Diphtheria CRM197 Conjugate, Pneumococcal Polysaccharide Serotype 33F - Diphtheria CRM197 Conjugate, Pneumococcal Polysaccharide Serotype 8 - Diphtheria CRM197 Conjugate, Pneumococcal Polysaccharide Serotype 9N - Diphtheria CRM197 Conjugate, Pneumococcal Polysaccharide Serotype 10A - Diphtheria CRM197 Conjugate, Pneumococcal Polysaccharide Serotype 11A - Diphtheria CRM197 Conjugate, Pneumococcal Polysaccharide Serotype 12F - Diphtheria CRM197 Conjugate, Pneumococcal Polysaccharide Serotype 17F - Diphtheria CRM197 Conjugate and 9 more
Therapeutic areas Vaccines
Conditions Prevention of disease caused by Streptococcus pneumoniae
Decision P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)
Published Apr 30, 2024
MHRA record cms.mhra.gov.uk

About MHRA paediatric investigation plans

A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.

Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date:

Browse all MHRA paediatric investigation plans